OpenPharma/pharma-kb-obesity
Pharma KB — Obesity Drug Landscape A structured pharmaceutical knowledge base covering the obesity drug pipeline — compiled from public regulatory, clinical, and scientific sources. Designed for RAG pipelines, competitive intelligence workflows, and pharma-domain LLM fine-tuning. Overview Indication Obesity (ICD: E66) Drug articles 285 (all phases, launched through discovery) Company articles 248 Target articles 35 Full content size ~11 MB… See the full description on the dataset page: https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity.
Pharma KB — Obesity Drug Landscape
A structured pharmaceutical knowledge base covering the obesity drug pipeline — compiled from public regulatory, clinical, and scientific sources. Designed for RAG pipelines, competitive intelligence workflows, and pharma-domain LLM fine-tuning.


Overview
Phase distribution (285 drugs):
Top pipeline positions (activity score, 0–100):
- Eli Lilly and Company — 86.84
- Novo Nordisk — 86.44
- Hanmi Pharmaceutical — 34.39
Sample Article
Drug articles are markdown files with structured frontmatter and narrative body:
---
title: semaglutide (subcutaneous, diabetes/obesity/NASH), Novo Nordisk
type: drug
slug: semaglutide
phase: Launched
originator: Novo Nordisk A/S
mechanism: Glucagon-like peptide 1 receptor agonist
indication_count: 10
fda_approval_count: 4
ct_trial_count: 215
targets:
- glucagon-like-peptide-1-receptor
indications:
- obesity
- non-insulin-dependent-diabetes
- metabolic-dysfunction-associated-steatohepatitis
# ... more fields
---The body covers mechanism of action, clinical trial history, regulatory milestones (FDA/EMA/PMDA), competitive context, deal activity, and preprint evidence.
Dataset Structure
pharma-kb-obesity/
├── indications/
│ └── obesity.md # Landscape overview, pipeline phases, deal velocity
├── drugs/ # 277 drug articles — all phases
│ ├── semaglutide.md
│ ├── tirzepatide.md
│ ├── cagrilintide.md
│ └── ...
├── companies/ # 248 company articles with pipeline positions
│ ├── eli-lilly.md
│ ├── novo-nordisk.md
│ └── ...
├── targets/ # 35 target articles
│ ├── glucagon-like-peptide-1-receptor.md
│ ├── gastric-inhibitory-polypeptide-receptor.md
│ └── ...
├── MANIFEST.md # Resolve URLs for all 569 articles (for direct fetch)
└── data/
└── train.parquet # Structured index — one row per entityEach article is a markdown file with YAML frontmatter and a narrative body covering mechanism, clinical status, regulatory history, and competitive context.
Usage
Load the index
from datasets import load_dataset
ds = load_dataset("OpenPharma/pharma-kb-obesity", split="train")
df = ds.to_pandas()
# Filter: Phase 3 drugs
phase3 = df[(df["entity_type"] == "drug") & (df["phase"] == "Phase 3")]
print(phase3[["slug", "title", "mechanism", "originator"]])Fetch any article directly
Every article has a stable resolve URL:
https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity/resolve/main/companies/eli-lilly.md
https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity/resolve/main/drugs/tirzepatide.md
https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity/resolve/main/indications/obesity.mdA full listing of all 569 resolve URLs is available at `MANIFEST.md`.
Clone for full article access
git clone https://huggingface.co/datasets/OpenPharma/pharma-kb-obesityRAG pipeline
from huggingface_hub import snapshot_download
from pathlib import Path
repo_path = Path(snapshot_download("OpenPharma/pharma-kb-obesity"))
# Load all articles as documents
documents = []
for md_file in repo_path.rglob("*.md"):
documents.append({
"text": md_file.read_text(),
"source": str(md_file.relative_to(repo_path)),
})
# Feed into LlamaIndex, LangChain, or any embedding pipelineRead a specific article
import yaml
from pathlib import Path
def parse_article(path):
content = Path(path).read_text()
_, fm_raw, body = content.split("---", 2)
return yaml.safe_load(fm_raw), body
fm, body = parse_article(repo_path / "drugs/semaglutide.md")
print(fm["phase"], fm["mechanism"])
print(body[:500])What's in Each Article
Drug articles include:
- Phase, mechanism of action, originator, indication coverage
- FDA approval history (approvals, label cross-checks)
- Clinical trial counts (ClinicalTrials.gov cross-referenced)
- Regulatory conflicts and data quality flags
- Aliases (brand names, INN variants, trial codes)
- Industry research attention — rolling 7-day attention rank and relative research activity vs. peers across the obesity landscape
Company articles include:
- Drug count and phase distribution per indication
- Activity score and tier across indications
- Deal counts and partnership history
- Investment Profile — public/private status, ticker (exchange + symbol), total capital raised, latest funding round, key investors, and recent pipeline/deal developments sourced from public financial data
- Competitive drug watchlist — the drugs this organization viewed most over the trailing 7-day window (predominantly other companies' drugs, surfacing competitive interest)
Target articles include:
- Gene symbol, protein family, disease associations
- Drugs targeting this mechanism with phase summary
- Literature and patent coverage notes
Indication article includes:
- Full pipeline phase distribution and trend analysis
- Company activity rankings with scores
- Mechanism class distribution (GLP-1 RA, GIP RA, GCGR, amylin, etc.)
- Deal velocity and top deal activity by type
- Industry research activity — ranked heatmap of research attention across top drugs in the landscape for the trailing 7-day window
Structured Index Schema
data/train.parquet — one row per entity (569 rows total):
Data Sources
This dataset is synthesized from the following public sources:
- ClinicalTrials.gov — trial counts, recruitment status, phase mapping
- FDA — drug approvals, labels, FAERS, patents
- EMA — European approvals and regulatory milestones
- PubMed — scientific literature
- ChEMBL — mechanism of action, ADMET, structure data
- bioRxiv / medRxiv — preprints
- UniProt — target biology
- Open Targets — disease-target associations
All data is synthesized and structured — not a direct export from any single source.
Releases
More Indications
Additional indication datasets (MASLD/NASH, cardiovascular, oncology) are in progress under the OpenPharma organization.
License
CC BY-NC 4.0 — free for research and non-commercial use with attribution.
Citation
If you use this dataset in your work, please cite:
@dataset{pharma-kb-obesity-2026,
title = {Pharma KB — Obesity Drug Landscape},
year = {2026},
url = {https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity},
license = {CC BY-NC 4.0}
}